PASCAL Precision Transcatheter Valve Repair System
Edwards Lifesciences, LLC · Decision date Sep 14, 2022
What did the FDA approve?
The FDA database entry for P220003 records an approval decision dated September 14, 2022 for the PASCAL Precision Transcatheter Valve Repair System from Edwards Lifesciences, LLC. The decision field is APPR, and the product code is NKM under the cardiovascular specialty.
The statement describes the device as indicated for percutaneous reduction of significant, symptomatic mitral regurgitation (MR >= 3+) due to primary abnormality of the mitral apparatus, described as degenerative MR, in patients determined by a heart team to be at prohibitive risk for mitral valve surgery. The heart team includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and existing comorbidities must not preclude the expected benefit from reduction of the MR. The entry does not state whether this decision is an original PMA or a supplement, and no supplement type or reason is supplied.
FDA approval order statement
Approval for the PASCAL Precision Transcatheter Valve Repair System. This device is indicated for the percutaneous reduction of significant, symptomatic mitral regurgitation (MR >= 3+) due to primary abnormality of the mitral apparatus (degenerative MR) in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the MR.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 14, 2022
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220003
- Regulatory pathway
- Premarket approval application
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NKM
- Decision code
- APPR
- Decision date
- Sep 14, 2022
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mitral valve repair devices.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NKM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220003 received
Application receipt date recorded by FDA.
P220003 · FDA decision
APPR
P220003/S033 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
P220003/S028 · Related supplement
PASCAL Ace with Capture Clarity Valve Repair System MR Implant System
P220003/S029 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
P220003/S032 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
Timeline entries are records held by MedtechLedger for P220003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Sep 9, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 20, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P220003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records